QIAGEN Announces New President for QIAGEN Japan
News Jan 28, 2009
QIAGEN N.V. has announced that Stephane Perrey has joined the Company as President of its fully-owned subsidiary QIAGEN KK on January 1, 2009. He follows Kazuo Tokushige, who retired on December 31st, and will lead QIAGEN’s further expansion in life sciences and the growing market of molecular diagnostics in Japan.
Dr Perrey joined the company from Third Wave/Hologic Japan and previously held various positions in the Japanese in-vitro diagnostic industry (especially in infectious diseases segments). He was also involved in the development of the first personalized medicine in-vitro diagnostic product to be approved in Japan. Stephane Perrey holds a Ph.D. in Medical Science from the University of Tokyo and completed his post-doc at Harvard Medical School.
In his new position at QIAGEN, Dr Perrey will assume responsibility for the company’s overall business activities in Japan.
“Stephane brings to QIAGEN a wealth of experience in the Japanese life science and molecular diagnostic industry, and we are pleased to have him on our team”, said Peer M. Schatz, QIAGEN’s CEO. The markets for our products in academic and pharmaceutics research, applied testing and molecular diagnostics are very attractive in Japan and we look forward to growing our already very sizable presence in this area.”
“Stephane has a strong track record in our customer segments in Japan” said Bernd Uder, Senior Vice President of Global Sales at QIAGEN. “His unique profile combines a strong scientific background with in-depth Japanese business experience. This blend is an excellent formula for our future success in the region.”
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE
New Cell-weighing Technique Helps Predict How Drugs Affect Cancer CellsNews
Researchers at MIT have now shown that they can use a new type of measurement to predict how drugs will affect cancer cells taken from multiple-myeloma patients.READ MORE
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE